Toxic encephalopathy in a clinicl case of polycythemia vera
https://doi.org/10.20538/1682-0363-2019-4-249-255
Abstract
The article deals with a clinical case description of a female patient with toxic encephalopathy against the background of Ph-negative myeloproliferative diseases. The article discusses symptoms and neuroimaging of hepatic encephalopathy developed as a result of a shunt placed after portal vein thrombosis. The issues of etiology and pathogenesis of hepatic encephalopathy, principles of therapy, as well as the unique clinical picture of nervous system damage in this condition are also discussed. Data on the role of manganese in development of toxic encephalopathy, accumulation of paramagnetic substance in the basal ganglia of the brain and development of extrapyramidal symptoms are presented. The pathogenesis of toxic damage to neurons, increase in their sensitivity to hypoxia, and the relationship with the risk of cerebrovascular disorders and development of chronic cerebral ischemia, contributing to reduction of cognitive functions, are described.
About the Authors
P. I. Kuznetsova
Research Center of Neurology
Russian Federation
Russian Federation
PhD, Researcher, 1st Neurological Department,
80, Volokolamskoe Shosse, Moscow, 125367
M. M. Tanashyan
Research Center of Neurology
Russian Federation
Russian Federation
DM, Professor, Head of the 1st Neurological Department, Deputy Director for Scientific Work,
80, Volokolamskoe Shosse, Moscow, 125367
A. A. Kornilova
Research Center of Neurology
Russian Federation
Russian Federation
Post-Graduate Student, 1st Neurological Department,
80, Volokolamskoe Shosse, Moscow, 125367
References
1. Barbui T., Thiele J., Gisslinger H., Finazzi G., Vannucchi A.M., Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Reviews. 2016; 30 (6): 453–459. DOI: 10.1016/j.blre.2016.06.001.
2. Tanashyan M.M., Kuznetsova P.I., Lagoda O.V., Shabalina A.A., Subortseva I.N., Melikyan A.L. Myeloproliferative disorders and ischemic stroke. Annaly Klinicheskoj i Eksperimental’noj Nevrologii. 2014; 8 (2): 41–45 (in Russ.).
3. Melikyan A.L., Turkina A.G., Kovrigina A.M. et al. Clinical recommendations on diagnosis and therapy of Ph-negative myeloproliferative disorders (polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia)(edition of 2016). Gematologiya i Transfuziologiya. 2017; 62 1(S1): 25–60 (in Russ.).
4. Shawcross D.L., Dunk A.A., Jalan R., Kircheis G., de Knegt R.J. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. European Journal of Gastroenterology & Hepatology. 2015; 28 (2): 146–152. DOI: 10.1097/MEG.0000000000000529.
5. Gundling F., Zelihic E., Seidl H. et al. How to diagnose hepatic encephalopathy in the emergency department. Ann. Hepatol. 2013; 12 (1): 108–114.
6. Ong J.P., Aggarwal A., Krieger D. et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am. J. Med. 2003; 114 (3): 188–193. DOI: 10.1016/s0002-9343(02)01477-8.
7. Kramer L., Tribl B., Gendo A. et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology. 2000; 31 (1): 30–34. DOI: 10.1002/hep.510310107.
8. Sharma P., Sharma B.C. Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Saudi J. Gastroenterol. 2012; 18 (3): 168–172. DOI: 10.4103/1319-3767.96448.
9. Gluud L.L., Vilstrup H., Morgan M.Y. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst. Rev. 2016; 4: Cd003044. DOI: 10.1002/14651858.CD003044.pub4.
10. Primignani M., Mannucci M. The role of thrombophiliain splanchnic vein thrombosis. Semin. Liver Dis. 2008; 28(3): 293–301. DOI: 10.1055/s-0028-1085097.
11. Garcia-Pagбn J.C., Hernбndes-Guerra M., Bosch J. Extrahepatic portal vein thrombosis. Semin. Liver Dis. 2008; 28 (3): 282–292. DOI: 10.1055/s-0028-1085096.
12. Hoekstra J., Janssen H.L. Vascular liver disorders (II): portal vein thrombosis. Neth. J. Med. 2009; 67 (2): 46–53.
13. Poddar U., Borkar V. Management of extra hepatic portal venous obstruction (EHPVO): current strategies. Trop. Gastroenterol. 2011; 32 (2): 94–102.
14. Fandeev Е.Е., Lyubivyj Е.D., Gonsalves G.D., ysoeva Е.P., Kitsenko Е.A. Extrahepatic portal hypertension and portal vein thrombosis (literature review). Annaly Hirurgicheskoj Gepatologii. 2015; 20 (1): 45–58. (in Russ.)]. DOI: 10.16931/1995-5464.2015145-58.
15. Srivastava A., Yadav S.K., Lal R., Yachha S.K., Thomas M.A., Saraswat V.A., Gupta R.K. Effect of surgical portosystemic shunt on prevalence of minimal hepatic encephalopathy in children with extrahepatic portal venous obstruction: assessment by magnetic resonance imaging and psychometry. J. Pediatr. Gastroenterol. Nutr. 2010; 51 (6): 766–772. DOI: 10.1097/MPG.0b013e3181ecaf62.
16. Butterworth R.F., Spahr L., Fontaine S. et al. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab. Brain Dis. 1995; 10(4): 259–267.
17. Hazell A.S. Astrocytes and manganese neurotoxicity. Neurochem. Int. 2002; 41: 271–277. DOI: 10.1016/s0197-0186(02)00013-x.
18. Sarkar S., Malovic E., Harischandra D.S., Ngwa H.A., Ghosh A., Hogan C., Kanthasamy A. Manganese exposure induces neuroinflammation by impairing mitochondrial dynamics in astrocytes. NeuroToxicology. 2018; 64: 204–218. DOI: 10.1016/j.neuro.2017.05.009.19. Young R.R., Shahani B.T. Asterixis: one type of negative myoclonus. Adv. Neurol. 1986; 43: 137–156.
19. Agarwal R., Baid R. Asterixis. J. Postgrad. Med. 2016; 62: 115–117.
Review
For citations:
Kuznetsova P.I., Tanashyan M.M., Kornilova A.A. Toxic encephalopathy in a clinicl case of polycythemia vera. Bulletin of Siberian Medicine. 2019;18(4):249-255. (In Russ.) https://doi.org/10.20538/1682-0363-2019-4-249-255
Views:
1115
Email this article 